December 18th, 2017

Next
A full text version of this article is available.
To access article obtain online access here or login
 
Title:
Abortifacient Effect of Decreased Decidual and Placental Galectin-1 Expression due to Metoclopramide Exposure in Pregnant Rats
Authors:  Yasemin Cekmez, M.D., Vakkas Korkmaz, M.D., Aslı Çakır, M.D., Ahmet Göçmen, M.D., Yusuf Ergün, M.D., and Serdar Gülsen, M.D.
  OBJECTIVE: To investigate the abortifacient effect of metoclopramide on decidual and trophoblastic tissues with immunohistochemical investigation of galectin-1 expression in pregnant rats.

STUDY DESIGN: A total of 24 pregnant rats were selected for the study and divided into 3 groups as untreated, low-dose (1 mg/kg) metoclopramide applied, and high-dose (3 mg/kg) metoclopramide applied from days 5–15 of pregnancy. All rats were laparotomized on day 19 of pregnancy, and num-ber of implantation sites, resorption, and dead or alive fetuses were recorded for evaluating abortifacient activity. Galectin-1 expression was investigated from decidual and trophoblastic tissues via immunohistochemical staining.

RESULTS: The mean percentage of abortion was detected higher in the high-dose group than both control and low-dose groups. Galectin-1 staining was more intense and universal in the untreated group than both high- and low-dose metoclopramide exposed groups in labyrinth trophoblasts and decidual tissue.

CONCLUSION: Metoclopramide exposure, especially in high doses, may cause abortion, and this drug should be recommended for use during pregnancy only when the benefit outweighs the risk.
Keywords:  abnormalities, drug-induced/epidemiology; abortifacient agents; abortifacients; abortion; antiemetics/adverse effects; decide; fetal death/chemically induced; Galectin-1; metoclopramide; metoclopramide/adverse effects; pregnancy; teratogens; trophoblasts
   
   
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from